

END TB

2022 TB CONFERENCE

MARCH 2-5, 2022
Virtual, Pacific Standard Time

The Union-North America Region

SUPPORTING ORGANIZATIONS

The Union

International Union Against Tuberculosis and Lung Disease
Health solutions for the poor



BC LUNG FOUNDATION



EDUCATIONAL GRANTS PROVIDED BY

Pittsfield Anti-Tuberculosis Association

PLATINUM SPONSOR



SILVER SPONSOR



EXHIBITORS

emocha Health®



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Curry International Tuberculosis Center and The Union-North America Region. The Curry International Tuberculosis Center is accredited by the ACCME to provide continuing medical education for physicians. This educational conference is approved for up to **19.75** continuing education hours.

The Curry International Tuberculosis Center designates this educational activity for a maximum of **19.75 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Curry International Center is approved as a provider of continuing education by the California State Board of Registered Nurses,

Provider CEP 12308. This educational conference is approved for up to **19.75** continuing education hours. Board requirements prevent us from offering CE credit to people who arrive more than 15 minutes after the start of the educational conference or leave the educational conference early. Therefore, **partial credit will not be awarded**.

Certificates will be available on the Curry International Tuberculosis Center website approximately twelve weeks after the educational conference to all participants who successfully complete the activity. Successful completion includes attending the entire educational conference and completing an online evaluation. To view your certificate, you will need to go to the training page on the Curry International Tuberculosis Center <https://www.currytbcenter.ucsf.edu/trainings>, log in and click on "training history".

All CME recipients will be contacted 4 months after the educational conference to assist with long-term evaluation activities.

FOR POST-CONFERENCE INQUIRIES CONTACT:

Menn Biagtan, MD, MPH
Conference Secretariat

E: biagtan@bclung.ca | T: (778) 994-7754



Messages	3
Keynote Lectures	4
Lifetime Achievement Awards	6
Service Awards	7
Pittsfield Anti-Tuberculosis Association's International Travel Grant Awardees	8
North American Region Travel Grant Awardees	9
Early Career Investigator Award	10
Committees	11
2022 Faculty	13
Poster Sessions Facilitators	14
Poster Sessions Schedule	14
Program (Daily Schedule)	15



Kevin Schwartzman, MD, MPH
President, The Union-North America Region

On behalf of The Union-North America Region, I am delighted to welcome you to our 26th Annual End TB Conference. The conference is a highlight every year and showcases key advances in TB science and practice from our region and around the world. Our conference planning committee, expertly led by Dr. Sarah Brode and ably supported by the BC Lung Association, has assembled a topnotch program. It spans the full spectrum of research and care, from the laboratory to the clinic to the public health department. Our conference provides wonderful opportunities to connect with colleagues and friends, new and old; to share experiences; and to learn from one another. We also honor our distinguished awardees for their leadership, innovation, and dedication. I look forward to seeing you and to enjoying our conference together!



Sarah Brode, MD, MPH
2022 Program Chair/
Vice-President, The Union-North America Region

We hope you will join us for END TB: The 26th Annual Conference of The Union – North America Region! This year’s program, put together by our multidisciplinary planning committee, will cover critical topics in TB prevention and care, including how TB programs can get back on (a faster!) track after COVID-19, meeting the needs of TB patients beyond TB, TB and Indigenous Peoples, up-to-date science and clinical aspects of TB transmission and the immune response, and implementing shorter regimens for active TB. We are also excited to include keynote addresses from Dr. Marcel Behr on Rethinking Latent TB Infection and Dr. Anne Schuchat on Public Health Leadership. The program will also include a session on challenging clinical TB cases chaired by an expert panel. We also hope you will join us early for our pre-conference postgraduate course on NTM pulmonary disease, antimicrobial susceptibility testing in TB, and the new Canadian TB Standards. Our audience always includes a diverse group of TB advocates, survivors, scientists, clinicians, and program managers, and we look forward to networking and discussing the latest in TB!

The George Comstock Lecture acknowledges Dr. Comstock's pioneering work and leadership over many decades. His direct and personal involvement in advanced research of tuberculosis spanned the period of early BCG trials to the modern era of molecular biology. His steadfast advocacy and tremendous depth of wisdom solidly based on experience was a guiding force for all health workers in the various fields of tuberculosis research all around the world, not only in the United States. His mentorship led us to many fruitful investments in research in tuberculosis prevention. This year's George Comstock Lecture is presented by Dr. Marcel Behr.



Dr. Marcel Behr

Dr. Behr is a clinician-scientist with appointments of Full Professor in the Department of Medicine and Associate member in the departments of Epidemiology and Biostatistics as well as Microbiology and Immunology. He is the founding Director of the McGill International TB Centre and led it from 2012 to 2018. He is the Associate Program Leader of the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the McGill University Health Centre since 2016 and in 2017 he became the co-Director the McGill Interdisciplinary Initiative in Infection and Immunity (McGill-i4). He is the interim director of McGill Infectious Diseases Division.

Dr. Behr trained at the University of Toronto, Queen's, McGill and Stanford. His work has been recognized by election into the Canadian Academy of Health Sciences, the Royal Society of Canada, the American Society for Clinical Investigation and the American Academy of Microbiology. Dr. Behr's lab uses bacterial genomic methodologies to study the epidemiology and pathogenesis of tuberculosis and other mycobacterial diseases.

When The Union was founded in 1920, the organizers rallied around the dream of eliminating tuberculosis as a public health threat. Since that time, we have seen the development and implementation of the DOTS strategy, the identification of linkages between poverty and TB, and the introduction of new technologies. Yet, TB remains a global threat. The Beyond TB Lecture of The Union-NAR conference serves to focus attention on forces outside the traditional TB world, assisting us to look beyond the usual partners, usual paths, and usual solutions to innovation and novel public health strategies to achieve our goal - A World Free of TB. This year's Beyond TB Lecture will be presented by Dr. Anne Schuchat.

Dr. Anne Schuchat

Dr. Anne Schuchat is an internist and epidemiologist whose career at the Centers for Disease Control and Prevention spanned 33 years. She was the agency's Principal Deputy Director from 2015-2021 and served twice as acting CDC director. From 2006-2015, she was the first Director of CDC's National Center for Immunization and Respiratory Diseases (NCIRD), leading the nation's immunization program through recommendations for several new vaccines and the global deployment of vaccines against pneumonia and meningitis. Prior to becoming NCIRD director, Dr. Schuchat was Chief of the Respiratory Diseases Branch from 1998-2005. She first joined CDC as an Epidemic Intelligence Service officer in 1988. She's been instrumental in decades of CDC emergency responses including the COVID-19 pandemic, the 2019 outbreak of vaping associated lung injuries, the 2009 H1N1 influenza pandemic, and the 2003 SARS outbreak where she deployed to Beijing. She collaborated on meningitis, pneumonia, and Ebola vaccine trials in West Africa and surveillance and prevention projects in South Africa. In the 1990's,



Dr. Schuchat spearheaded the effort to establish guidelines for the prevention of newborn infections from group B streptococcus, saving an estimated 100,000 newborns from infection with this pathogen. Her contributions have been recognized by election to the National Academy of Medicine, receipt of the USPHS Distinguished Service Medal, and the Association of State and Territorial Health Officials Lifetime Achievement Award and as a finalist for the Paul A. Volcker Career Achievement Medal from the Partnership for Public Service. Dr. Schuchat retired as a Rear Admiral in the Commissioned Corps of the United States Public Health Service in 2018 and from the CDC in 2021.

The **Lifetime Achievement Award** of the Union-North America Region is the highest award given by the region. It is presented to recipients who have made an outstanding contribution in the field of Tuberculosis over an entire career. The contribution may have been in any aspect of TB, including basic science, epidemiology, public health, advocacy, patient care, education, nursing, and laboratory science. Nominees may be working in any position, organization, or profession.

The **Service Awards** are given to individuals who have made a significant contribution to the field of TB. This award may be given annually. Recipients may include administrators, educators, and public health advisors, as well as nurses and physicians.



Dr. Edward Anthony Nardell

Dr. Nardell has devoted his 40-year career to tuberculosis control through both public health and clinical interventions. Dr. Richard Riley mentored his longstanding focus on airborne transmission of infections in buildings, now including COVID-19, and engineering control interventions, including germicidal air disinfection. Dr. Mel First and colleagues at Harvard School of Public Health, and Dr. Phil Brickner in New York City were other key mentors. Early in his career he hired a young man as a Creole-speaking outreach worker named Paul Farmer – leading to a global health TB control focus, especially the treatment of highly drug-resistant strains. To these and many other mentors and colleagues he is forever grateful.



Dr. Charles M. Nolan

Dr. Nolan worked in public health in Seattle for 30 years, focusing on the epidemiology, prevention and control of tuberculosis. During his tenure at Seattle Public Health, Dr. Nolan participated in the teaching programs of the University of Washington's Schools of Medicine and Public Health, where he is now Emeritus Clinical Professor of Medicine. He is past Chair of the HHS Advisory Council for the Elimination of Tuberculosis, and Past President of the Board of Trustees of the International Union North American Chapter. He was a member of the World Health Organization Green Light Committee for access to second line anti-tuberculosis medications, and from 2004-09 provided oversight to the Gates Foundation on the CREATE Project, a \$75 Million grant to an international consortium to improve the control of TB and HIV/AIDS in southern Africa. During his years in Seattle, Charlie has served on the Boards of The Pacific Science Center, the Seattle Foundation, Seattle Art Museum, and the Fred Hutchinson Cancer Research Center.



Dr. Joan Mangan

Dr. Mangan is a Senior Behavioral Scientist with CDC's Division of Tuberculosis Elimination. Joan began her career as a laboratorian with the North Broward Hospital District in Ft. Lauderdale, Florida. While working with the hospital district she earned a Master of Science in Teaching, with a focus on biological sciences and served as a Regional Laboratory Manager.

She later earned her doctorate in Health Behavior from the University of Alabama at Birmingham.

Prior to joining CDC in 2011, Joan was an Assistant Professor with the Division of Pulmonary, Allergy, and Critical Care Medicine – Lung Health Center at the University of Alabama at Birmingham and a Research Assistant Professor in the Department of Medicine at the University of Florida.



Dr. Thomas Wong

Dr. Wong is the Chief Medical Officer of Public Health and the Chief Science Officer at Indigenous Services Canada. He was trained in family medicine, internal medicine, infectious diseases and public health at McGill, Harvard and Columbia. He has academic appointments at both the University of Ottawa and the University of Toronto.



Ms. Nicola Nero

Nicola Nero is from Guyana, South America, and works at the National TB Programme, Ministry of Health. She has 26 years of public health experience including Nursing administration. She believes that the importance of evidence-based information is necessary to guide planners to strategically make decision in all aspects of the health sector. Nicola plans to continue embarking on research aimed at promoting best practice for improved patient care. She currently holds a master's degree in nursing.



Ms. Katherine Pena-Valencia

Katherine Pena-Valencia is a Biologist and doctoral student at the University of Antioquia in Medellin, Colombia. Her study is focuses on the microbiome's role in lung disease and its relationship with the immune response. She is interested in community work aimed at promoting spaces for discussion and feedback on scientific knowledge, something she calls "neighborhood science."



Dr. Milo Richard

Dr. Milo Richard is a Haitian physician born in Haiti who graduated at the Medical school of the Haiti State University in 1996; after his social service in 1997 he worked for HHF outreach clinic that supports the poor in the southwest of Haiti. After his internship in pulmonary medicine he started to work for the NTP of Haiti in 2005 as a care manager; then he moved to Taiwan for his Master in public health to go back to the NTP as the head of monitoring and evaluation service for the ministry of Health of Haiti.



Dr. Phenila Rogers

Phenila Rogers is a new Family Medicine specialist with 14 years of successful experience as a General Practitioner. She is currently employed by the main referral hospital in Guyana – Georgetown Public Hospital Corporation – where she provides patient-centered primary health care at a community level. Her strong faith in God and compassion for people is the foundation of everything she does both professionally and personally. Phenila enjoys a good sitcom binge and spending time with family.



Nancy Bedingfield

Nancy is a PhD Candidate in the Cumming School of Medicine, University of Calgary. She is also the local coordinator for 2 clinical trials underway in Calgary examining shorter, rifamycin-based latent TB treatments. Nancy is a registered nurse with varied experiences in public health and over a decade of focused practice in TB. She is interested in education and counselling for TB patients and family members, implementation science, and qualitative and mixed research methods.



Dr. Melanie Dubois

Dr. Melanie Dubois is a third-year pediatric infectious disease fellow at Boston Children's Hospital. She is an early career investigator interested in improving TB care delivery for pregnant women and children living in high burden HIV/TB settings.



Isabel Foster

Isabel Foster is a Research and Policy Officer with the GloPID-R Scientific Secretariat based at the University of Oxford. Before joining GloPID-R, Isabel worked as a Research fellow at the International Development Research Centre (IDRC) where her work focused on coordinating One Health research funding in low- and middle-income countries. Isabel has also worked on the secretariat of the Government of Canada's Scientific Advisory Committee on Global Health across a range of global health issues. Her research interests lie in interventions to mitigate the stigmatization of infectious diseases to curb disease outbreaks. She holds an MSc. in Global Health jointly received from Universities McMaster and Maastricht.



Coralie Geric

Coralie Geric completed a B.Sc in Mathematics and Statistics at the University of Victoria, followed by an M.Sc in Public Health at McGill University in 2021. Coralie is currently a Research Assistant at the Research Institute of the McGill University Health Centre, working with Dr. Faiz Ahmad Khan in the Translational Research in Respiratory Diseases Program. Coralie's recent work focuses on evaluating artificial intelligence-based software used to detect pulmonary TB on chest radiographs.



Juliana Kim

Juliana Kim is currently a second-year medical student at Rutgers Robert Wood Johnson Medical School. She graduated from Brown University in 2020 with a double major in Visual Art and Biology, where she investigated the role RNA splicing in disorders such as autism under mentorship of Dr. William Fairbrother. In medical school, she expanded to translational and clinical educational research. She hopes to use these skills in her future career as a physician-scientist.



Mariane Saroufim

Mariane Saroufim is graduate student at McGill University pursuing a master's in public health. She is currently a Research Trainee at the Research Institute of the McGill University Health Centre. Her research includes assessing the impact of occupation on active tuberculosis (TB) infections in low-income neighborhood of Karachi in Pakistan. Her other research interests include epidemiology and data analysis, vaccine equity, decolonizing global health research and improving disease control in low- and middle-income countries.



Amanda Sullivan

Amanda Sullivan is a clinical research assistant II at Beth Israel Deaconess Medical Center. She has a master's in public health degree from Tufts University concentrating in epidemiology and biostatistics. Primary research interests include TB diagnostics, prevention, and social determinants of health.



Nawang Yanga

Nawang Yanga recently completed her MA in Health Policy and Equity at York University. Her major research paper took on a comparative analysis of TB policies and programmes in Tibetan refugee settlements and Indigenous communities in Canada. Her interest in TB is inextricably tied to her Tibetan identity, as a friend and family member to various TB survivors. She is currently working with Stop TB Canada to develop a peer support network for people affected by TB in Canada called TB Conquerors.



Devin Zebelean

Devin Zebelean is an MPH candidate at Boston University. She works for Dr. Karen Jacobson's research group at Boston Medical Center. She is working with several research studies that focus on Tuberculosis or COVID-19. Their primary study site for Tuberculosis is in Worcester, South Africa, and COVID-19 work at Boston, MA, USA. This is the first academic conference that she will be attending and is excited to learn more about current research in this field.

EARLY CAREER INVESTIGATOR AWARD



Dr. Devan Jaganath

Dr. Jaganath is an Assistant Professor of Pediatrics at the University of California, San Francisco. He received his MD at UCLA and a master's degree in public health (MPH) at Johns Hopkins University. He subsequently completed a pediatrics residency at Johns Hopkins and his fellowship in pediatric infectious diseases at UCSF. His interests have focused on improving the care of children with TB and LTBI, locally and internationally. In particular, he leads several initiatives to discover and validate novel diagnostics for pulmonary TB in children and examines the role of digital health to improve LTBI and TB disease screening, diagnosis, and treatment in community-based and primary care settings.

THE UNION-NAR EXECUTIVE COMMITTEE

Kevin Schwartzman, MD, MPH
President
McGill University
Montreal, QC, Canada

Lisa Chen, MD
President-Elect
University of California
San Francisco, SF, CA, USA

Menn Biagtan, MD, MPH
Secretariat
British Columbia
Lung Association
Vancouver BC, Canada

Sarah Brode, MD, MPH
Program Chair/Vice-President
University of Toronto
Toronto, ON, Canada

C. Robert Horsburgh, MD
Boston University
School of Public Health
Boston, MA, USA

Christopher Lam
Ex-Officio
British Columbia
Lung Association
Vancouver, BC, Canada

Jonathan Golub, PhD, MPH
Secretary/Treasurer
Johns Hopkins School
of Public Health
Baltimore, MD, USA

Lisa V. Adams, MD
Immediate Past
Vice-President
Geisel School of Medicine
Dartmouth, Hanover, NH, USA

2022 ABSTRACT COMMITTEE

Jonathan Golub, PhD, MPH
Chair
Johns Hopkins School
of Public Health
Baltimore, MD, USA

Victoria Cook, MD
BC Centre for Disease Control
Vancouver, BC, Canada

Joan Mangan, PhD, MPH
Centers for Disease Control and
Prevention, Atlanta, GA, USA

Lisa Armitige, MD, PhD
Heartland National TB Center
San Antonio, TX, USA

Rachel Dwirow, MD
University of Manitoba
Winnipeg, MB, Canada

E. Ann Misch, MD
University of Wisconsin School
of Medicine and Public Health
Madison, WI, USA

Rajita Bhavaraju, PhD, MPH
NJMS Global Tuberculosis
Institute at Rutgers
Newark, NJ, USA

Ryan Cooper, MD
University of Alberta
Edmonton, AB, Canada

Eyal Oren, PhD, MS
San Diego State University
San Diego, CA, USA

E. Jane Carter, MD
Brown University
Providence, RI, USA

Charlie M. Crane, MD, MPH
Martinez, CA, USA

Elizabeth Talbot, MD
Geisel School of Medicine at
Dartmouth, Hanover, NH, USA

C. Robert Horsburgh, MD
Boston University
School of Public Health
Boston, MA, USA

Sheela Shenoj, MD, MPH
Yale School of Medicine
New Haven, CT, USA

2022 CME PLANNING COMMITTEE

Sarah Brode, MD, MPH
Program Chair/Vice-President
University of Toronto
Toronto, ON, Canada

Carolyn Bargman, RN
Denver, CO, USA

Richard Brostrom, MD
Centers for Disease Control
and Prevention
Honolulu, HI, USA

Lisa Chen, MD
University of California
San Francisco
San Francisco, CA, USA

Victoria Cook, MD
BC Centre for Disease Control
Vancouver, BC, Canada

Maziar Divangahi, PhD
McGill University
Montreal, QC, Canada

Kevin Fennelly, MD
National Institutes
of Health
Bethesda, MD, USA

Jonathan Golub, PhD, MPH
Johns Hopkins School
of Public Health
Baltimore, MD, USA

C. Robert Horsburgh, MD
Boston University
School of Public Health
Boston, MA, USA

Anita Khilall, MPH
Global Tuberculosis Institute
Rutgers, Newark, NJ, USA

Alfred Lardizabal, MD
NJMS Global Tuberculosis
Institute at Rutgers
Newark, NJ, USA

David Lewinsohn, MD, PhD
Oregon Health & Science
University, Portland, OR, USA

Joan Mangan, MPH, PHD
Centers for Disease Control
and Prevention
Atlanta, GA, USA

Sundari Mase, MD
Department of Health Services
Santa Rosa, CA, USA

Sapna Morris, MD
Centers for Disease Control
and Prevention
Atlanta, GA, USA

Sonal Munsiff, MD
University of Rochester
Medical Center
Rochester, NY, USA

Kelly Musoke, MPH
University of California
San Francisco
San Francisco, CA, USA

Ann Raftery, RN, PHN
Curry International
Tuberculosis Center
Oakland, CA, USA

Elizabeth Rea, MD
Toronto Public Health
Toronto, ON, Canada

Max Salfinger, MD
University of South Florida
College of Public Health
Tampa, FL, USA

Cynthia Tschampl, PhD
Brandeis University
Waltham, MA, USA

Elizabeth Talbot, MD
Geisel School of Medicine
at Dartmouth
Hanover, NH, USA

Wendy Wobeser, MD
Queens University
Kingston, ON, Canada

Isa Wolf, RN
TB Program
Saskatoon, SK, Canada

Dr. Gonzalo Alvarez
University of Ottawa
Ottawa, ON, Canada

Dr. Marcel Behr
McGill University
Montreal, QC, Canada

Ms. Tina Campbell
Northern Inter-Tribal
Health Authority,
Prince Albert, SK, Canada

Dr. Ryan Cooper
University of Alberta
Edmonton, AB, Canada

Dr. Lucica Ditiu
Stop TB Partnership
WHO, Geneva, Switzerland

Dr. Maziar Divangahi
McGill University
Montreal, QC, Canada

Dr. Susan Dorman
Medical University of South
Carolina, Charleston, SC, USA

Dr. Rachel DwiLOW
University of Manitoba
Winnipeg, MB, Canada

Ms. Virginia Etsitty
Navajo Nations Tuberculosis
Navajo, NM, USA

Dr. Dennis Falzon
World Health Organization
Geneva, Switzerland

Dr. Jennifer Flood
University of California
San Francisco
San Francisco, CA, USA

Dr. Salah Foraida
TB Alliance
New York, NY, USA

Ms. Francine Gascoyne
First Nations Health Authority
Lady Smith, BC, Canada

Dr. David Griffith
National Jewish Health
Denver, CO, USA

Billie-Jo Hardy, PhD
University of Toronto
ON, Canada

Dr. Courtney Heffernan
University of Alberta
Edmonton, AB, Canada

Dr. Jonathan Iralu
Brigham and Women's
Hospital, Boston and
University of New Mexico
Navajo, NM, USA

Dr. James Jonhston
BC Centre for Disease Control
Vancouver, BC, Canada

Mr. Caleb Klipowicz
University of Iowa
Iowa City, IA, USA

Dr. Claudio Köser
University of Cambridge
Cambridge, UK

Dr. David Lewinsohn
Oregon Health and
Science University
Portland, OR, USA

Dr. Janice K. Louie
University of California
San Francisco
San Francisco, CA, USA

Dr. Peter MacPherson
Liverpool School of Tropical
Medicine, Liverpool, UK

Dr. Dick Menzies
Montreal Chest Institute,
McGill International TB Centre
Montreal, QC, Canada

Dr. Alexandra Molnar
University of Washington
School of Medicine
Seattle, WA, USA

Dr. Ilaria Motta
Medicines San Frontières, UK

Dr. Masa Narita
University of Washington
Seattle, WA, USA

Dr. Barbara Seaworth
Heartland National TB Center
San Antonio, TX, USA

Dr. Anne Schuchat
Centers for Disease Control and
Prevention, Atlanta, GA, USA

Dr. Irini Sereti
National Institute of Health
Bethesda, MD, USA

Dr. Caroline Williams
University of Leicester
Leicester, UK

Ms. Sara Young
BC Centre for Disease Control
Vancouver, BC, Canada

POSTER SESSION FACILITATORS

PEDIATRIC

Lisa Armitige, MD, PhD
Heartland National TB Center
San Antonio, TX, USA

Ian Kitai, MD
Hospital for Sick Children
Toronto, ON, Canada

SPECIAL POPULATIONS

Victoria Cook, MD
BC Centre for Disease Control
Vancouver, BC, Canada

Richard Brostrom, MD
Centers for Disease Control and
Prevention, Honolulu, HI, USA

CO-MORBIDITIES / RISK FACTORS / EPI

Jonathan Golub, PhD, MPH
Johns Hopkins School of
Public Health
Baltimore, MD, USA

SCREENING & TREATMENT

C. Robert Horsburgh, MD
Boston University School
of Public Health
Boston, MA, USA

QUALITATIVE / POLICY & ADVOCACY

Joan Mangan, MPH, PHD
Centers for Disease Control
and Prevention
Atlanta, GA, USA

SCIENCE

E.Jane Carter, MD
Brown University
Providence, RI, USA

COVID

Elizabeth Talbot, MD
Geisel School of Medicine
at Dartmouth
Hanover, NH, USA

Sundari Mase, MD
Department of Health Services
Santa Rosa, CA, USA

POSTER SESSION SCHEDULE

THURSDAY, MARCH 3, 2022

1:00-2:00 PM

- COVID
- Co-Morbidities
- Qualitative/Policy/Advocacy
- Pediatric

FRIDAY, MARCH 4, 2022

1:00-2:00 PM

- Science
- Risk Factors/Epidemiology
- Special Populations
- Screening and Treatment

DAILY SCHEDULE

WEDNESDAY, MARCH 2, 2022

Postgraduate Course – 1:00PM – 4:30PM PST
Chairs: Dr. Max Salfinger and Ms. Anita Khilall

1:00 – 1:05

Welcome Remarks

1:05 – 2:05

The Canadian TB Standards: What's New and Improved in the 8th Edition – Sneak Preview

Dr. Dick Menzies

Montreal Chest Institute and McGill

International TB Centre, Montreal, QC, Canada
Dr. James Johnston, BC Centre for Disease
Control, Vancouver, BC, Canada

2:05 – 2:15

Short Break

2:15 – 3:15

Critical Issues in Phenotypic and Genotypic Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex

Dr. Claudio Köser

University of Cambridge, Cambridge, UK

3:15 – 3:25

Short Break

3:25 – 4:25

Challenges in Diagnosis and Treatment of NTM Pulmonary Disease

Dr. David Griffith

National Jewish Health, Denver, CO, USA

4:25 – 4:30

Closing Remarks

THURSDAY, MARCH 3, 2022

MORNING SESSION – 8:00AM – 12:00PM PST

8:00 – 8:10

Welcome Remarks

Dr. Sarah Brode, 2022 Program Chair,
Vice-President, The Union-NAR
Dr. Kevin Schwartzman, President
The Union-NAR

8:10 – 8:15

Opening Prayer

Syexwaliya Ann Whonnock
Squamish Nation Elder

8:15 – 8:25

Patient Perspective

Ms. Kate O'Brien

TB Survivor (We Are TB)

8:30 – 9:30

Keynote: The George Comstock Lecture: Rethinking Latent TB Infection

Dr. Marcel Behr

McGill University, Montreal, QC, Canada

9:30 – 11:55

STOP TB SESSION: Back on a Faster Track

Chairs: Dr. Elizabeth Rea, Dr. Sundari Mase,
and Dr. Cynthia Tschampl

9:30 – 9:35

Introduction

9:35 – 10:05

Impacts of COVID on TB Globally and How to Get Back on Track

Dr. Dennis Falzon, World Health Organization
Geneva, Switzerland

10:05 – 10:10

Short Break

10:10 – 10:40

How Much Money We Need to End TB?

Dr. Lucica Ditiu, Stop TB Partnership
Geneva, Switzerland

THURSDAY, MARCH 3, 2022

10:40 – 10:45

Short break

10:45 – 11:20

Computer-assisted CXR Detection for TB Screening

Dr. Peter McPherson, Liverpool School of Tropical Medicine, Liverpool, UK

11:20 – 11:30

Oral Abstract Presentation: Chest X-ray Screening in Prediction and Prevention for Incident Cases Among TB-Exposed Children

Dr. Qi Tan, Harvard Medical School Boston, MA, USA

11:30 – 11:55

Panel Discussion

12:00 – 12:55

Non-CME Activity: Industry Sponsored Satellite Symposium—Qiagen

AFTERNOON SESSION – 1:00PM – 5:30PM PST

1:00 – 1:55

POSTER SESSION

2:00 – 4:30

Nursing Sponsored Session:

Meeting the Needs of TB Patients Beyond TB

Chairs: Ms. Carolyn Bargman, Ms. Ann Raftery, Ms. Isa Wolf

2:00 – 2:05

Introduction

2:05 – 2:35

Decolonizing TB: Holistic Approaches with Indigenous Communities

Ms. Francine Gascoyne, First Nations Health Authority, Lady Smith, BC, Canada

2:35 – 2:40

Short break

2:40 – 3:20

Supporting Resilience through Trauma-informed Approaches: Lessons for TB Prevention and Care

Dr. Alexandra Molnar, University of Washington School of Medicine, Seattle, WA, USA

3:20 – 3:25

Short break

3:25 – 3:55

Improving Patient Outcomes: Partnering with Harm Reduction Services

Ms. Sara Young, BC Center for Disease Control Vancouver, BC, Canada

3:55 – 4:05

Oral Abstract Presentation: Post-Tuberculosis Depression Risk and the Role of Hospital Length of Stay: A Population-Based Cohort Study of People Immigrating to British Columbia, Canada, 1985-2015

Christopher Andrew Basham, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada

4:05 – 4:25

Panel Discussion

4:30 – 5:30

Award Ceremony

FRIDAY, MARCH 4, 2022

7:30 – 8:30

STOP TB Canada/STOP TB USA Meetings

MORNING SESSION – 8:30AM – 12:00PM PST

8:30 – 12:00

TB Transmission Science and Isolation Policy

Chairs: Dr. Kevin Fennelly and Dr. Sonal Munsiff

8:30 – 8:35

Introduction

8:35 – 9:15

Respiratory Pathogen Transmission: Lessons from the Slow Pandemic

Dr. Caroline Williams, University of Leicester, Leicester, UK

9:15 – 9:20

Short break

9:20 – 9:50

TB Infectiousness and the Impact of Treatment

Dr. Ryan Cooper, University of Alberta Edmonton, AB, Canada

9:50 – 9:55

Short break

9:55 – 10:25

TB Hospitalization and Diagnosis in Low Incidence Settings

Dr. Jennifer Flood, University of California San Francisco, San Francisco, CA, USA

10:25 – 10:35

Oral Abstract Presentation: Tuberculosis Treatment Adherence in the Era of COVID-19

Dr. Maunank Shah, Johns Hopkins University Baltimore, MD, USA

10:35 – 10:55

Panel Discussion

10:55 – 11:00

Short break

11:00 – 12:00

Keynote: THE BEYOND TB LECTURE: Public Health Leadership in 2022

Dr. Anne Schuchat, Centers for Disease Control and Prevention, Atlanta, GA, USA

12:00 – 1:00

Lunch Break

AFTERNOON SESSION – 1:00 – 4:30PM PST

1:00 – 2:00

POSTER SESSION

2:00 – 4:30

TB and Indigenous Peoples

Chairs: Dr. Wendy Wobeser and Dr. Richard Brostrom

2:00 – 2:05

Introduction

2:05 – 2:25

Ethical Engagement and Indigenous Research Methodologies and Implications for TB Research

Dr. Billie-Jo Hardy, University of Toronto Toronto, ON, Canada

Ms. Tina Campbell, Northern Inter-Tribal Health Authority, Prince Albert, SK, Canada

Dr. Courtney Heffernan, University of Alberta, Edmonton, AB, Canada

2:25 – 2:35

Oral Abstract Presentation: Developing Data Governance Agreements with Indigenous Communities in Canada Towards Equitable Tuberculosis Programming, Research, and Reconciliation

Mr. Robin Love, University of Alberta, Edmonton, AB, Canada

2:35 – 2:50

Q/A

FRIDAY, MARCH 4, 2022

2:50 – 3:00
Short break

3:00 – 3:30
Treating Tuberculosis in Indian Country During the Pandemic
Dr. John V. Iralu, Brigham and Women’s Hospital Boston and University of New Mexico Navajo, NM, USA
Ms. Virginia Etsitty, Navajo Nation Navajo, NM, USA

3:30 – 3:55
Mass Screening for Latent Tuberculosis Infection and Active Tuberculosis in Children < 16 years old in Nunavut, Canada
Dr. Rachel DwiLOW, University of Manitoba Winnipeg, MB, Canada

3:55 – 4:00
Short break

4:00 – 4:25
Colonialisms Past and Present: Key Lessons from TB Control among Marshall Islanders (1885 – today)
Mr. Caleb Klipowicz, Department of Anthropology University of Iowa, Iowa City, IA, USA

SATURDAY, MARCH 5, 2022

MORNING SESSION – 8:00AM – 11:55AM PST

8:00 – 9:25
Challenging TB Cases-Joint Medical, Nursing and Public Health
Chairs: Dr. Victoria Cook, Dr. Elizabeth Talbot, Dr. Sapna Morris, Dr. Alfred Lardizabal, and Ms. Cheryl Giffin

9:30 – 11:55
Implementing Short Regimens for TB
Chairs: Dr. Alfred Lardizabal, Dr. Lisa Chen, Dr. Victoria Cook

9:30 – 9:35
Introduction

9:35 – 10:35
Overview of Break-through Studies

9:35 – 9:55
Drug Sensitive TB: 4mo Study 31 Regimen
Dr. Susan Dorman, Medical University of South Carolina, Charleston, SC, USA

9:55 – 10:15
Drug-Resistant TB: Final NIX and Early ZENIX Results
Dr. Salah Foraida, TB Alliance, New York, NY, USA

10:15 – 10:35
Drug Resistant TB: PRACTECAL Results
Dr. Ilaria Motta, Médecins Sans Frontières, UK

10:35 – 10:45
Short break

10:45 – 11:55
Rapid-Fire: What’s Next? Early Implementation Insights

10:45 – 10:55
Rifapentine Access: Update for Canadian Programs
Dr. Gonzalo Alvarez, University of Ottawa Ottawa, ON, Canada

10:55 – 11:05
Study 31: Programmatic Early Adopter Experience
Dr. Janice K. Louie, University of California San Francisco, San Francisco, CA, USA

11:05 – 11:15
BPAL: US Program Implementation Experience
Dr. Masa Narita, Public Health - Seattle & King County, University of Washington Seattle, WA, USA

11:15 – 11:20
Short break

11:20 – 11:30
Oral Abstract Presentation: Interventions to Mitigate Common Non-Communicable Diseases among People Who Experience Tuberculosis: A Scoping Review of the Evidence
Ms. Kamila Romanowski, BC Centre for Disease Control, Vancouver, BC, Canada

11:30 – 11:55
Panel Discussion: Let’s Talk: Study Authors + Implementers QA

12:00 – 12:55 PM
Annual General Meeting

AFTERNOON SESSION – 1:00PM – 3:30PM PST

1:00 – 3:30
The Immune System and TB
Chairs: Dr. David Lewinsohn and Dr. Maziar Divangahi

1:00 – 1:05
Introduction

1:05 – 1:30
How Immune Response to TB is Guiding Vaccine Development
Dr. David Lewinsohn, Oregon Health & Science University, Portland, OR, USA

1:30 – 1:35
Short Break

1:35 – 2:00
Can We Train Innate Immunity Against TB?
Dr. Maziar Divangahi, McGill University Montreal, QC, Canada

2:00 – 2:05
Short Break

2:05 – 2:30
Mycobacterial IRIS in People with HIV: Beyond What Meets the Eye
Dr. Irini Sereti, National Institute of Health Bethesda, MD, USA

2:30 – 2:35
Short Break

2:35 – 3:00
Non-HIV TB IRIS; Recognizing and Battling Both the Bug and the Inflammation
Dr. Barbara Seaworth, Heartland National TB Center, San Antonio, TX, USA

3:00 – 3:10
Oral Abstract Presentation: Cytomegalovirus Acquisition in Infancy and the Risk of Tuberculosis Disease in Childhood: A Longitudinal Birth Cohort in Cape Town, South Africa
Dr. Leonardo Martinez School of Public Health Boston University, Boston, MA, USA

3:10 – 3:30
Panel Discussion

3:30 – 4:30
Post Conference Meeting

**SAVE
THE DATE**

**FEBRUARY
22-25
2023**

END TB 2023 CONFERENCE
Sheraton Wall Centre Hotel, Vancouver, BC